224 citations
,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
193 citations
,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
153 citations
,
April 2009 in “Urology” Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
148 citations
,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
93 citations
,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
91 citations
,
July 2004 in “Journal of Biological Chemistry” Overexpressing SSAT enzyme reduces prostate tumor growth in mice.
89 citations
,
December 2006 in “Lancet Oncology” Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
72 citations
,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
71 citations
,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
67 citations
,
December 2015 in “Journal of the National Comprehensive Cancer Network” The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
57 citations
,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
56 citations
,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
50 citations
,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
49 citations
,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
44 citations
,
January 2012 in “Food and chemical toxicology” Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
43 citations
,
August 2016 in “Scientific Reports” Cinnamomi cortex may help treat prostate enlargement by reducing related proteins.
38 citations
,
February 2011 in “Annals of Oncology” Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
33 citations
,
October 2004 in “Archives of Dermatological Research” Large prostate links to more hair loss, but age of onset doesn't affect it.
31 citations
,
September 2015 in “BJUI” Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
30 citations
,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
29 citations
,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
28 citations
,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.